As an example, in a CD33+ AML patient, alloHSCT with CD33negative HSPCs along with anti-CD33-CAR T cell therapy can eradicate the CD33+ blasts without effect on CD33neagative HSPCs which results in reducing the hematopoietic toxicity [114, 193]. This evidence concerns the gene CD33 and acute myeloid leukemia.